Clinical Report: Pyridostigmine for Pediatric Chronic Intestinal Pseudo-Obstruction

Overview

This case study presents a 9-year-old girl with an ACTL6B mutation who experienced significant gastrointestinal improvement following pyridostigmine therapy for chronic intestinal pseudo-obstruction. The findings suggest a potential link between ACTL6B-related disorders and gastrointestinal dysmotility.

Background

ACTL6B mutations are associated with various neurodevelopmental disorders, but gastrointestinal manifestations, particularly motility disorders, have not been well characterized. Pediatric chronic intestinal pseudo-obstruction (PIPO) is a severe condition that can lead to significant morbidity and mortality. Understanding the potential role of pyridostigmine in managing PIPO could enhance treatment options for affected patients.

Data Highlights

The introduction of pyridostigmine led to improved enteral feeding tolerance, a marked reduction in vomiting episodes, and stabilization of nutritional status in the patient.

Key Findings

• Pyridostigmine is an acetylcholinesterase inhibitor that enhances cholinergic transmission and improves gastrointestinal motility.
• The patient with ACTL6B mutation showed significant improvement in gastrointestinal symptoms after starting pyridostigmine therapy.
• PIPO is characterized by ineffective propulsion of gastrointestinal contents without mechanical obstruction, often leading to severe dysmotility.
• Cholinergic medications like pyridostigmine may offer therapeutic benefits in pediatric patients with suspected neuropathic gastrointestinal dysmotility.
• Further investigation is needed to confirm the link between ACTL6B mutations and gastrointestinal dysmotility.

Clinical Implications

Pyridostigmine may be considered as an adjunctive therapy for pediatric patients with chronic intestinal pseudo-obstruction, particularly when a neuropathic component is suspected. Clinicians should monitor for cholinergic side effects and adjust dosing based on individual patient response.

Conclusion

Highlight specific research areas needed to explore the genetic-gastrointestinal link.

References

1. Author(s)/Org, Source, Year -- Title
2. Cossins J., PMC, 2025 -- Dose escalation pre-clinical trial of novel DOK7-AAV in mouse model of DOK7 congenital myasthenia
3. Author(s)/Org, Brain, 2025 -- Dysfunction of ATP1A3 Leads to Increased Motor Excitability and Loss of Afterhyperpolarization in a Model of Dystonia
4. Author(s)/Org, Acta Neuropathologica, 2014 -- Neuropathological and Neuroanatomical Investigation of Rapid-Onset Dystonia-Parkinsonism Linked to the I758S Mutation in the ATP1A3 Gene in Four Siblings
5. ESPGHAN Expert Group, PubMed, 2025 -- Paediatric Intestinal Pseudo-obstruction: Evidence and Consensus-based Recommendations
6. Author(s)/Org, Pediatric Drugs, 2026 -- Therapeutic Role of Neostigmine and Pyridostigmine in Pediatric Chronic Intestinal Pseudo-Obstruction: A Systematic Review
7. Author(s)/Org, Frontiers in Medicine, 2025 -- Phenotype and genotype in hereditary chronic intestinal pseudo-obstruction with small intestine involvement
8. Paediatric Intestinal Pseudo-obstruction: Evidence and Consensus-based Recommendations From an ESPGHAN-Led Expert Group - PubMed
9. Therapeutic Role of Neostigmine and Pyridostigmine in Pediatric Chronic Intestinal Pseudo-Obstruction: A Systematic Review | Pediatric Drugs | Springer Nature Link
10. Phenotype and genotype in hereditary chronic intestinal pseudo-obstruction with small intestine involvement